No Data
CEL-SCI Met With Saudi Food And Drug Authority, Says Is Preparing To Submit A Regulatory Filing For The Approval Of Multikine As A Neoadjuvant Treatment Of Newly Diagnosed Previously Untreated Locally Advanced Head And Neck Cancer
CEL-SCI to File for Regulatory Approval of Multikine in Saudi Arabia-Pursuing Local Partnerships for Commercialization and Manufacturing to Serve Middle East and North Africa Market
With Young Adult Cancer on the Rise, New Therapies Spark Investor Buzz
CEL-SCI Says Publication Supports Strategy to Seek Early Approval for Multikine
Express News | CEL-SCI Announces Publication From Prior 3 Study Of Multikine In Journal 'Pathology and Oncology Research'
CEL-SCI Reports New Data: Treatment With Multikine Resulted in up to 95% Improvement in Quality of Life for Head and Neck Cancer Patients
